Resistant variants of human immunodeficiency virus type 1 (HIV-1) have been selected by limited passage in MT4 cells of both wild-type and 3'-azido-3'-deoxythymidine (AZT, zidovudine)-resistant strains with the nucleoside analogues (-)-2'-deoxy-3'-thiacytidine (3TC) and (-)-2'-deoxy-5-fluoro-3'-thiacytidine (FTC). Virus variants selected independently were crossresistant to both inhibitors. This rapid in vitro selection of resistant virus has not previously been seen with nucleoside analogues but is reminiscent of that observed with the nonnucleoside reverse transcriptase inhibitors. However, passage of wild-type virus with a combination of AZT and FTC appreciably delayed emergence of FTCresistant virus. DNA sequence analysis of the reverse transcriptase coding region from FTC-resistant virus revealed changes at codon 184 in the highly conserved Tyr, Met, Asp,
influence of this mutation in a background of mutations conferring resistance to AZT and nonnucleoside reverse transcriptase inhibitors, a series of HIV-1 variants were created by site-directed mutagenesis. All mutants with Met'84 -Val were crossresistant to 3TC and FTC. The Met'84-Val mutation did not influence nevirapine resistance, but resistance to AZT was suppressed. Similar suppression of AZT resistance was seen with Tyrl8l -+ Cys. Interestingly, when both Met'84 Val and Tyr'8' -* Cys substitutions were present, highly resistant virus reverted to complete AZT sensitivity. Assessment of the interactive effects of multiple drug-resistance mutations may help to establish a rationale for using these drugs in the future therapy of HIV disease.
The development and clinical use of selective inhibitors to treat human immunodeficiency virus (HIV) infection have been marred by the ability of the virus to become drug resistant (1) . This first became apparent during analysis of clinical isolates from individuals with acquired immunodeficiency syndrome (AIDS) receiving long-term 3'-azido-3'-deoxythymidine (AZT, zidovudine) therapy (2) . Resistant variants have also emerged during prolonged monotherapy with the two other "first-generation" nucleoside analogue HIV inhibitors: 2',3'-dideoxyinosine (ddI) (3, 4) and 2',3'-dideoxycytidine (ddC) (5) . Interestingly, it has proved difficult or impossible to derive HIV-1 strains highly resistant to nucleoside analogues by exposure of virus in cell cultures to these inhibitors (6) (7) (8) . In contrast, however, resistance de- The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
velops rapidly in culture to the newly described group of HIV-1 specific nonnucleoside reverse transcriptase (NNRT) inhibitors, including the tetrahydroimidazobenzodiazepinones and -thiones (TIBOs) (9) , pyridinones (10) (3) . In the presence of AZT mutations this Val74 substitution had a suppressive effect on AZT resistance. During ddC therapy a single RT mutation at codon 69 also resulted in partial resistance (5-fold) (5) . Commonly, resistance to the NNRT inhibitors is due to a single substitution at codon 181 in RT (Tyr --Cys), although mutations in other regions of RT, particularly between residues 100 and 108, have been described (9) (10) (11) 15) . The codon 181 mutation also suppresses AZT resistance when present in a genetic background of AZT-resistance mutations (9) .
A second generation of nucleoside analogue inhibitors has been described recently that have more diverse modifications than previous compounds, particularly to the sugar, in an attempt to improve selectivity for greater safety during long-term therapy. These include the 3'-thiacytidine or 3'-oxathialane cytosine analogues (-)-2'-deoxy-3'-thiacytidine (3TC) (16) and (-)-2'-deoxy-5-fluoro-3'-thiacytidine (FTC) (17) (Structure I). In both cases, the "unnatural" L sugar configuration, or (-) enantiomer, is the most potent and selective form (17, 18) . The triphosphate derivatives of these nucleosides are inhibitors ofHIV-1 RT, presumably accounting for the antiviral activity (17, 19 these inhibitors, we examined the effect of AZT on development of FTC resistance. In addition, after determining the genetic basis of this resistance, we examined the influence of the FTC/3TC-resistance mutation on virus susceptibility to inhibitors when incorporated into virus variants with AZTand/or NNRT inhibitor-resistance mutations.
MATERIALS AND METHODS Cells and Vhrus. Two human lymphoblastoid T-cell lines were used: MT-4 to propagate HIV-1 for in vitro selection of resistant virus and MT-2 (20) for electroporation experiments. Cells were maintained in RPMI 1640 medium supplemented with 10%o (vol/vol) fetal bovine serum plus antibiotics. Human CD4+ HeLa cells, HT4LacZ-1 (21) were used to assess virus sensitivity to inhibitors by plaque reduction (22) . This cell line was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10%6 fetal bovine serum plus antibiotics. The HIV-1 strains used in these studies were the wild-type virus HXB2, derived from the molecular clone pHXB2-D (23), and two AZT-resistant mutants and one NNRT inhibitor-resistant mutant, constructed by sitedirected mutagenesis of the RT coding region in pHXB2-D. The AZT-resistant mutants were HIVRTMC (12) , with the RT substitutions Asn67, Arg70, Phe215, and Gln219, and HIVRTMN (14) , with Leu41 and Tyr215. The NNRT inhibitorresistant mutant was HXB2(181C) (9), with Cys181. Cell-free virus supernatants were stored at -70°C.
Compounds. The 3'-thiacytidine nucleosides were synthesized at Wellcome Laboratories, and the (-) and (+) enantiomers were purified to >99% purity as described (17) . Nevirapine was a gift from Boerhinger Ingelheim, and ddl and ddC were purchased from Sigma. All compounds were dissolved in dimethyl sulfoxide at 40 mM and diluted in culture medium immediately before use.
Sensitivity Assays by Plaque Reduction in HT4LacZ-1 Cells. These were performed as described (22) (PCR) . The product was sequenced directly between codons 40 and 108 and between codons 170 and 225 by using specific oligonucleotide primers as described (9) . In addition, the entire RT coding region was obtained by PCR from HXB2 passaged six times in FTC, cloned into M13, and sequenced around the codon 184 region as described (12) .
Construction of Recombinant HIV-1 Variants. Site-directed mutagenesis using synthetic oligonucleotides (7) introduced mutations into the RT coding region of wild-type virus and a number of AZT-or NNRT inhibitor-resistant variants cloned in M13. Clones were analyzed for expression of functional RT in Escherichia coli (7) . Recombinant HIV-1 variants were obtained after cotransfection of RT mutant M13 DNA and the RT-deleted provirus clone pHIVARTBstE11 into MT-2 cells (14) . IC5o values of passage 6 virus were in excess of 250 pM, representing a >1000-fold shift in sensitivity. These variants were also highly resistant to 3TC but showed no crossresistance to AZT, ddl, or nevirapine. Further virus passage studies, similar to the above but made with 3TC, also resulted in rapid development of highly resistant virus (Fig. 1B) that was crossresistant to FTC.
RESULTS AND DISCUSSION
If such rapid resistance also occurs in the clinic, this might severely limit the therapeutic value ofthese inhibitors, except possibly in combination with other HIV-1 inhibitors such as AZT. Therefore, to test this, we studied the effects of a combination of AZT and FTC on emergence of resistant virus during in vitro passage. AZT at 50 nM was able to delay, but not prevent, development of FTC-resistant virus (Fig. 1A) . This delay in emergence of resistance was also reflected in slower growth of the virus, which may be due in part to synergy observed in vitro between AZT and FTC (M. St.
Clair, personal communication). These data support the possible use of these compounds in combination therapy.
Genetic Analysis of Resistant HIV Variants Produced During Passage in MT-4 Cells. To discover the genetic basis of FTC resistance, we performed direct DNA sequence analysis within the RT coding region obtained by PCR amplification from virus-infected cells after six passages in FTC. FTC resistance appeared to be associated with a mutation at codon 184 of RT, since no other amino acid changes were observed in the regions sequenced. A mixture of nucleotides at codon 184 was seen, with both the FTC-passaged viruses, HXB2 and RTMC. The predominant GTG triplet predicts a Met -+ Val amino acid change ( (Table 2) . Thus, a single amino acid change can confer high-level resistance to a nucleoside analogue. This is in contrast to the single substitutions induced by ddl and ddC, which confer only a slO-fold change in sensitivity. Furthermore, at least four amino acid changes in RT are required to confer an 100-fold increase in resistance to AZT (12) (13) (14) .
Some crossresistance was also seen with the (+) enantiomers (D-sugar forms) of 3TC and FTC but was much less marked, with only a 5-to 15-fold increase in IC50 values. In addition, with nucleoside inhibitors containing normal bases and sugar analogues in the natural D form (ddl and ddC) only minimal changes in susceptibility were seen. Therefore, high-level resistance is associated with the (-) enantiomers or L-sugar forms of these nucleosides, suggesting that the recognition of these analogues by HIV-1 RT is highly specific.
Analysis of recombinant viruses containing combinations of mutations from different drug-resistant variants revealed some interesting effects on sensitivity to inhibitors ( The Met84 -. Val mutation was introduced into a number of AZT-or NNRT inhibitor-resistant variants in M13 by site-directed mutagenesis using synthetic oligonucleotides. All clones were analyzed for expression offunctional RT in E. coli and found to possess RT activity comparable to (within 2-fold of) wild type. Recombinant HIV-1 variants were obtained after cotransfection of RT mutant M13 DNA and the RT-deleted provirus clone pHIVARTBstE11 into MT-2 cells. Virus variants were titrated and compound sensitivity was determined by plaque reduction in the CD4+ HeLa cell line HT4LacZ-1. Some suppression of AZT resistance has been seen previously with the 181 mutation alone: RTMC, ICSo 1.5 ,uM; RTMC(181), ICso 0.5 ,uM (9) . Nev, nevirapine.
Tyr181 --Cys mutation (9) . Remarkably, when substitutions at both codon 181 and codon 184 were present in combination with four AZT-resistance mutations (substitutions at codons 67, 70, 215, and 219), complete suppression ofhigh-level AZT resistance occurred.
In conclusion, these data, together with reports of synergy between the 3'-thiacytidine inhibitors and AZTt and between AZT and nevirapine (28) , indicate that combination therapy with these inhibitors may be beneficial in the treatment of HIV-1 infection in AIDS. Such information from preclinical studies should assist in the more rational design oftrials in the clinical evaluation of these inhibitors. These studies further substantiate the importance of in vitro evaluation of the potential for development of resistance to "new" inhibitors. The Met184 -Val substitution has already been seen in one patient after 3TC treatment, indicating that the in vitro data may be predictive for the clinic (29) . Knowledge of the types of virus variants which may be generated during combination therapy and the effects resistance mutations have on drug susceptibility should be of value in adopting the best strategies for control of HIV-1 infection in the future.
